1) Demographic shifts are increasing the burden of chronic diseases which account for over 70% of healthcare costs. 2) Telemedicine, such as remote patient monitoring, can help address this by allowing patients to be monitored from home to improve outcomes and reduce costs. 3) Studies show remote patient monitoring can reduce hospital admissions by 19-32% and healthcare costs while improving quality of life for patients with conditions like COPD, diabetes and heart failure.
eHealth Summit: "Case Study: The applied research for connected health (ARCH)...3GDR
Slides from National eHealth Summit, 30 Sept 2015 at Carton House, Kildare: Maria Quinlan, Research Lead Change Work-Package, ARCH.
#eHealthSummit15
http://www.ehealthsummit.ie
http://mhealthinsight.com/2015/09/25/mhealth-insights-from-the-ehealth-summit/
The technologies of telehealth are advancing quickly as part of the ‘connected care’ revolution. Patients and health providers are ever more closely linked through real-time electronic tools. From digital imaging to allow remote viewing of CT scans, through to patient diagnosis, videoconferencing and monitoring, these tools could touch all aspects of the patient-provider relationship.
Much of the promise of telehealth is predicated on its ‘access’ benefits: the improved access of the patient to medical expertise regardless of location, and improved access of health providers to their patients, for the purpose of diagnosis, consultation and monitoring. Yet access to telehealth depends not only on telehealth technology. Policy frameworks must be modernised, communications infrastructures such as broadband and mobile network coverage must be improved, and skillsets – both of clinicians and patients – need to be strengthened. This briefing paper outlines three factors shaping the telehealth access environment: government readiness (e.g. legal and regulatory clarity and harmonisation, especially across states and borders), communications infrastructure, and skills.
eHealth Summit: "ICT Use in Irish General Practices: An Intra-Practice Adopti...3GDR
Slides from National eHealth Summit, 30 Sept 2015 at Carton House, Kildare: Jane Bourke, Lecturer in Economics, University College Cork.
#eHealthSummit15
http://www.ehealthsummit.ie
http://mhealthinsight.com/2015/09/25/mhealth-insights-from-the-ehealth-summit/
eHealth Summit: "Case Study: The applied research for connected health (ARCH)...3GDR
Slides from National eHealth Summit, 30 Sept 2015 at Carton House, Kildare: Maria Quinlan, Research Lead Change Work-Package, ARCH.
#eHealthSummit15
http://www.ehealthsummit.ie
http://mhealthinsight.com/2015/09/25/mhealth-insights-from-the-ehealth-summit/
The technologies of telehealth are advancing quickly as part of the ‘connected care’ revolution. Patients and health providers are ever more closely linked through real-time electronic tools. From digital imaging to allow remote viewing of CT scans, through to patient diagnosis, videoconferencing and monitoring, these tools could touch all aspects of the patient-provider relationship.
Much of the promise of telehealth is predicated on its ‘access’ benefits: the improved access of the patient to medical expertise regardless of location, and improved access of health providers to their patients, for the purpose of diagnosis, consultation and monitoring. Yet access to telehealth depends not only on telehealth technology. Policy frameworks must be modernised, communications infrastructures such as broadband and mobile network coverage must be improved, and skillsets – both of clinicians and patients – need to be strengthened. This briefing paper outlines three factors shaping the telehealth access environment: government readiness (e.g. legal and regulatory clarity and harmonisation, especially across states and borders), communications infrastructure, and skills.
eHealth Summit: "ICT Use in Irish General Practices: An Intra-Practice Adopti...3GDR
Slides from National eHealth Summit, 30 Sept 2015 at Carton House, Kildare: Jane Bourke, Lecturer in Economics, University College Cork.
#eHealthSummit15
http://www.ehealthsummit.ie
http://mhealthinsight.com/2015/09/25/mhealth-insights-from-the-ehealth-summit/
Current regulations regarding eHealth in Europe by Frank Lievens, Executive Secretariat ISfTeH Director, Managing Director Lievens-Lanckman bvba, Belgium
Health device makers, to date, have primarily targeted consumers who are either fitness focused or chronically ill. But between these two extremes sits a large, fragmented and often overlooked population who seek better information to effectively manage their health. Our research suggests that successful solution providers will approach this market opportunity as an ecosystem of partners – with an integrated solution that extends beyond the device itself. By plugging the information gap for these consumers, solution providers can help fuel healthcare innovation.
Chronic Care Improvement: How Medicare Transformation Can Save Lives, Save Mo...Steve Brown
Presentation by Steve Brown and Harris Miller introducing the ITAA Whitepaper: Chronic Care Improvement: How Medicare Transformation Can Save Lives, Save Money, and Stimulate an Emerging Technology Industry
Ross McKenna
Portfolio Manager, Health System Infrastructure
Information Strategy and Architecture
National Health Board Business Unit
Ministry of Health
Read about some of the innovative solutions we offer for better healthcareCGI
Delivering healthcare is one of the most complex human activities. In recent decades, major transitions have taken place in diagnostics, pharmaceuticals and treatments resulting in shorter length of stay in healthcare facilities. The current transition to more personalised care and to longer term managed care pathways means that healthcare IT systems are changing direction. But this change may not happen smoothly.
Read Logica’s paper on the need for convergence of healthcare and pharmaCGI
As the biggest industry sector in most European economies, healthcare is already given a big chunk of the gross domestic product (GDP). This portion is expected to become even bigger and have a huge impact on employment, the opportunities to grow businesses and economies in general.
This is a prescriptive / generic roadmap for telemedicine, that can be used by Governments , NGOs, companies & individuals in deploying telemedicine and mHealth solutions.
This roadmap was developed by a global team of 17 experts led by Rajendra Pratap Gupta under the Innovation Working Group -Asia (IWG-A).
IWG-A was set up by the office of the UN Secretary General to harness the power of innovations for Health , specially for health related MDGs.
More details write to ea2rajendragupta@gmail.com
"Healthcare Services at Merck & Co". Presentation by Guy Eiferman, President of Healthcare Services and Solutions, Merck & Co., made at the mHealth Israel Investors Summit, June 29, 2015, in Jerusalem
Current regulations regarding eHealth in Europe by Frank Lievens, Executive Secretariat ISfTeH Director, Managing Director Lievens-Lanckman bvba, Belgium
Health device makers, to date, have primarily targeted consumers who are either fitness focused or chronically ill. But between these two extremes sits a large, fragmented and often overlooked population who seek better information to effectively manage their health. Our research suggests that successful solution providers will approach this market opportunity as an ecosystem of partners – with an integrated solution that extends beyond the device itself. By plugging the information gap for these consumers, solution providers can help fuel healthcare innovation.
Chronic Care Improvement: How Medicare Transformation Can Save Lives, Save Mo...Steve Brown
Presentation by Steve Brown and Harris Miller introducing the ITAA Whitepaper: Chronic Care Improvement: How Medicare Transformation Can Save Lives, Save Money, and Stimulate an Emerging Technology Industry
Ross McKenna
Portfolio Manager, Health System Infrastructure
Information Strategy and Architecture
National Health Board Business Unit
Ministry of Health
Read about some of the innovative solutions we offer for better healthcareCGI
Delivering healthcare is one of the most complex human activities. In recent decades, major transitions have taken place in diagnostics, pharmaceuticals and treatments resulting in shorter length of stay in healthcare facilities. The current transition to more personalised care and to longer term managed care pathways means that healthcare IT systems are changing direction. But this change may not happen smoothly.
Read Logica’s paper on the need for convergence of healthcare and pharmaCGI
As the biggest industry sector in most European economies, healthcare is already given a big chunk of the gross domestic product (GDP). This portion is expected to become even bigger and have a huge impact on employment, the opportunities to grow businesses and economies in general.
This is a prescriptive / generic roadmap for telemedicine, that can be used by Governments , NGOs, companies & individuals in deploying telemedicine and mHealth solutions.
This roadmap was developed by a global team of 17 experts led by Rajendra Pratap Gupta under the Innovation Working Group -Asia (IWG-A).
IWG-A was set up by the office of the UN Secretary General to harness the power of innovations for Health , specially for health related MDGs.
More details write to ea2rajendragupta@gmail.com
"Healthcare Services at Merck & Co". Presentation by Guy Eiferman, President of Healthcare Services and Solutions, Merck & Co., made at the mHealth Israel Investors Summit, June 29, 2015, in Jerusalem
Innovative Healthcare Solutions: Enhancing Quality of Care for AllDragon Dream Bar
In the dynamic landscape of healthcare, the pursuit of innovative solutions is paramount to improving patient outcomes, enhancing efficiency, and reducing costs. “Healthcare Solutions” encompass a broad range of technologies, strategies, and practices aimed at addressing the diverse needs of patients, providers, and healthcare organizations. This comprehensive overview explores the evolving field of healthcare solutions and its transformative impact on the delivery of care.
Healthcare Effectiveness - Technological stepping stones to confront healthca...NEORIS
Healthcare Effectiveness, Technological stepping stones to confront healthcare challenges
Neoris Practical InSights
Robert Schotte
Neoris Commercial Director
Continuity in primary care and the use of technology, such as integrated EMR platforms, provide the required information to analyze patters of symptoms in order to trigger preventive measures, thus reducing the probabilities of future chronic or acute diseases.
AI in telemedicine: Shaping a new era of virtual healthcare.pdfStephenAmell4
In a rapidly evolving healthcare landscape, telemedicine has emerged as a transformative force, transforming the way healthcare is delivered and received. Telemedicine, also known as telehealth, is a mode of healthcare delivery that leverages modern communication technology to provide medical services and consultations remotely.
2016 IBM Interconnect - medical devices transformationElizabeth Koumpan
Emerging technologies such as Internet of Things, 3D Printing are driving the creation of new business models and forcing the Industry for transformation. The product centric model where the Industry main objective was to develop the device, is moving to software and services model, with the focus on Big Data & Analytics, Integration and Cloud.
The maturation of technologies such as social, mobile, analytics, cloud, 3D printing, bio- and nanotechnology are rapidly shifting the competitive landscape. These emerging technologies create an environment that is connected and open, simple and intelligent, fast and scalable. Organizations must embrace disruptive technologies to drive innovation
When developing a business strategy centered on the patient, organizations must adapt and implement programs that foster information sharing and collaboration while providing faster and greater access to life-changing products.
Similar to ECH Campus: Dr Sascha Henke (Bosch) (20)
HorseTech Conference Cheltenham 15/16 March 20223GDR
Speakers who will present on 15-16th March 2022 at the HorseTech Conference Cheltenham (and can be watched via the completely FREE livestream). For full details and to register:
https://horsetechconference.com/cheltenham/
DOCTORS AND SOCIAL MEDIA webinar (delivered by Liz Price, MDDUS senior risk a...3GDR
These slides were used for a MDDUS webinar that aimed to explore the legislative and regulatory risks involved in doctors personal and professional use of social media, and in relation to responding to and engaging with patients via this media.
The objectives were to raise awareness of the common medicolegal risks associated with doctors personal use of social media.
To raise awareness of the common medicolegal risks associated with doctors professional use of social media. To explore ways in which doctors can most appropriately respond to patient feedback and contacts via online platforms.
Participants are equipped to apply the knowledge gained in the webinar to risk assess and safely manage their online activities.
Provides guidance to enable improvement of personal practice in this area:
Royal Pharmaceutical Society UCL School of Pharmacy New Year Lecture 20193GDR
Diabetes and the Pharmacy Army
Philip Newland-Jones
Consultant Pharmacist Diabetes & Endocrinology
University Hospital Southampton NHS Foundation Trust
Mobile Health: the enable of Empowered Patients3GDR
Draft of slides for talk by David Doherty (coFounder, 3GDoctor) at the "Transforming Community Pharmacies in to High Street Clinics" Conference in London on the 15th November 2018.
For more information please visit:
https://mhealthinsight.com/2018/10/28/join-us-at-transforming-community-pharmacies-in-to-high-street-clinics/
Mobile Health: the enable of Empowered Patients3GDR
Draft of slides for talk by David Doherty (coFounder, 3GDoctor) at the "Transforming Community Pharmacies in to High Street Clinics" Conference in London on the 15th November 2018.
Slides for lecture by David Doherty (about.me/mHealth) to the Medical Students at University College Dublin on Thursday 29th March 2018.
Full details and Video:
https://mhealthinsight.com/2018/03/22/how-would-the-bornmobile-generation-redesign-medicine-and-whats-the-future-role-of-the-doctor/
Slides for lecture by David Doherty (about.me/mHealth) to the Medical Students at University College Dublin on Thursday 22 March 2018.
Full details and Video:
https://mhealthinsight.com/2018/03/22/how-would-the-bornmobile-generation-redesign-medicine-and-whats-the-future-role-of-the-doctor/
eHealth Ireland & Northern Ireland Connected Health Ecosystem
members of the ECHAlliance International Ecosystem Network
Cross Border Collaboration Projects in Action Alan Connor, mPower Programme Manager, NHS24
Notes on a talk on “Pricing and evaluating Orphan Drugs – present and future”...3GDR
The following slides are notes made by David Doherty following a very interesting presentation on “Pricing and evaluating Orphan Drugs – present and future” provided by Goran Medic, Market Access Manager Europe at Horizon Pharma Plc at the Pharma Pricing & Market Access Europe Conference in London (the world’s largest gathering of pharmaceutical pricing, market access and reimbursement professionals) on the 23rd February 2017.
Deriving more value from real world evidence to ensure timely access of medic...3GDR
Dr Sarah Wamala Andersson, Consultant, Real world evidence and value-based medicines
Pharma Pricing & Market Access Congress 2017 22 February 2017 London
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
1. Connected Health Market Development: Recent Results Connected Health Leadership Summit - 2009 Dr. Sascha Henke, Robert Bosch Healthcare
2.
3.
4. Connected Health Leadership Summit - 2009 1. Situation What is Telemedicine/Telehealth? Doc 2 Patient (RPM) Doc2Doc
5. Connected Health Leadership Summit - 2009 1. Situation What is Remote Patient Monitoring? Remote patient monitoring (RPM) uses devices to remotely collect / send data (using DSL, broadband, cellular, satellite networks or conventional telephone lines) to a monitoring station for interpretation. Such RPM applications include morbidity relevant vital signs, knowledge and behaviour as well as therapy management programs to monitor and manage behaviour of patients living at home or otherwise outside the expensive infrastructure of a hospital. Such services can be used to support any medical service providers as physicians, hospitals, disease management organizations and to supplement the use of visiting nurses.
![Connected Health Leadership Summit - 2009 ,[object Object],[object Object],[object Object],Agenda](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)